Bioorganic & Medicinal Chemistry Letters ( IF 2.7 ) Pub Date : 2018-08-25 , DOI: 10.1016/j.bmcl.2018.08.026 James Graham 1 , Christina E Wong 1 , Joshua Day 1 , Elizabeth McFaddin 1 , Urs Ochsner 1 , Teresa Hoang 1 , Casey L Young 1 , Wendy Ribble 1 , Mary A DeGroote 2 , Thale Jarvis 1 , Xicheng Sun 1
From a high throughput screening of commercially available libraries against nontuberculous mycobacteria and Mycobacterium tuberculosis, numerous hits were identified with moderate activity. Extensive medicinal chemistry optimization has led to a series of potent benzothiazole amide antimycobacterial agents. Replacement of the adamantyl group with cyclohexyl derivatives and further development of this series resulted in an advanced lead compound, CRS400393, which demonstrated excellent potency and a mycobacteria-specific spectrum of activity. MIC values ranged from 0.03 to 0.12 μg/mL against Mycobacterium abscessus and other rapid-grower NTM, and 1–2 μg/mL against Mycobacterium avium complex. The preliminary mechanism of action studies suggested these agents may target MmpL3, a mycobacterial mycolic acid transporter. The series has demonstrated in vivo efficacy in a proof of concept mouse model of M. abscessus infection.
中文翻译:
发现苯并噻唑酰胺作为有效的抗分枝杆菌剂
通过对市售非结核分枝杆菌和结核分枝杆菌文库的高通量筛选,鉴定出许多具有中等活性的命中。广泛的药物化学优化产生了一系列有效的苯并噻唑酰胺抗分枝杆菌药物。用环己基衍生物取代金刚烷基并进一步开发该系列产生了先进的先导化合物CRS400393,它表现出优异的效力和分枝杆菌特异性的活性谱。针对脓肿分枝杆菌和其他快速生长的 NTM 的MIC 值范围为 0.03 至 0.12 μg/mL ,针对鸟分枝杆菌复合体的 MIC 值范围为 1-2 μg/mL。初步作用机制研究表明这些药物可能以 MmpL3(一种分枝杆菌分枝菌酸转运蛋白)为目标。该系列已在脓肿分枝杆菌感染的概念验证小鼠模型中证明了体内功效。